Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A new model of early, integrated palliative care: palliative rehabilitation for newly diagnosed patients with non-resectable cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Nausea in advanced cancer: relationships between intensity, burden, and the need for help

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. 87-årig kvinde påkørt af flugtbilist og helbredt for højmalignt lymfom

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Posterior reversibel encefalopati efterbehandling af malignt lymfom

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. FDG-PET/CT after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: Results of a Nordic/US intergroup study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cerebralt aspergillom hos patient med immundefekt og follikulært lymfom

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: High-dose chemotherapy prior to autologous stem cell transplantation (ASCT) leads to adverse effects including mucositis, neutropenia and bacteremia. To reduce the toxicity, we treated myeloma and lymphoma patients with peroral bismuth as an adjuvant to chemotherapy to convey cytoprotection in non-malignant cells.

METHODS: This trial was a prospective, randomised, double-blind, placebo-controlled pilot study of hematological inpatients (n = 50) receiving bismuth or placebo tablets, in order to identify any potential superiority of bismuth on toxicity from chemotherapy.

RESULTS: We show for the first time that bismuth significantly reduces grade 2 stomatitis, febrile neutropenia and infections caused by melphalan in multiple myeloma, where adverse effects also were significantly linked to gender. In lymphoma patients, bismuth significantly reduces diarrhoea relative to placebo. Also, lymphoma patients' adverse effects were linked to gender. For the first time, bismuth is demonstrated as a safe strategy against chemotherapy's toxicity without interfering with intentional anti-cancer efficiency. Also, we show how gender significantly influences various adverse effects and response to treatment in both multiple myeloma and malignant lymphomas.

CONCLUSION: These results may impact clinical prevention of chemotherapy's cytotoxicity in certain patient groups, and also, this study may direct further attention towards the impact of gender during the course and treatment outcome of malignant disorders.

Original languageEnglish
JournalSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Volume25
Issue number4
Pages (from-to)1279-1289
ISSN0941-4355
DOIs
Publication statusPublished - Apr 2017

ID: 49836528